参仙升脉口服液联合单硝酸异山梨酯缓释胶囊治疗老年冠心病以及缓慢性心律失常的疗效研究

Effect of Shenxian Shengmai Oral Liquid(参仙升脉口服液) Combined with Isosorbide Mononitrate Capsule on Senile Coronary Heart Disease and Bradyarrhythmia

目的探讨参仙升脉口服液联合单硝酸异山梨酯缓释胶囊治疗老年冠心病以及缓慢心律失常患者的治疗效果。方法研究中选择100例2019年9月—2021年1月于辽宁中医药大学附属医院心内科入院治疗的老年冠心病及缓慢性心律失常患者为主要研究对象,根据选择的治疗方案不同,将其分成两组,其中一组将50例患者选择在基础治疗基础上,加入参松养心胶囊和单硝酸异山梨酯缓释胶囊治疗且将其设为常规组,其余50例患者选择在基础治疗基础上,加入参仙升脉口服液联合单硝酸异山梨酯缓释胶囊治疗,并设为研究组,观察两组治疗效果。结果研究组中医证候疗效总有效率更高(P<0.05);不良反应几率更低(P<0.05);治疗前,两组在心率指标及24 h动态心电图指标上比较无统计学意义(P>0.05);治疗后,研究组心率指标及24 h动态心电图更优于常规组(P<0.05);研究组的高切全血黏度、低切全血黏度及血浆黏度指标更优于常规组(P<0.05)。结论应用参仙升脉口服液联合单硝酸异山梨酯胶囊治疗老年冠心病及缓慢性心律失常效果显著,能够有效降低不良反应,具有一定的安全性,缓解临床症状,值得推广。

Objective To investigate the effect of Shenxian Shengmai Oral Liquid(参仙升脉口服液) combined with Isosorbitol Mononitrate Capsule in the treatment of elderly patients with coronary heart disease and bradyarrhythmia.Methods This study selected 100 cases in September 2019-January 2021 in Liaoning University of Traditional Chinese Medicine hospital affiliated hospital of cardiology of elderly patients with coronary heart disease and tardy arrhythmia as the main research object,according to different choice of treatment plan,it is divided into two groups,one group will choose on the basis of conventional treatment of 50 cases,to join "shensongyangxin capsule"And Isosorbide mononitrate sustained-release capsules were set as the conventional group.[u6]The remaining 50 patients were selected to be treated with Shenxian Shengmai oral liquid combined with Isosorbide mononitrate sustained-release capsules on the basis of conventional treatment,and were set as the study group to observe the therapeutic effect of the two groups.Results The total effective rate of traditional Chinese medicine syndrome in the study group was higher(P<0.05).The incidence of adverse reactions was lower(P<0.05).Before treatment,there was no significant difference in heart rate index or 24-hour dynamic electrocardiogram index between the two groups(P>0.05).After treatment,the heart rate index and 24-hour dynamic electrocardiogram index of the study group were better than those of the conventional group(P<0.05).The high shear whole blood viscosity,low shear whole blood viscosity and plasma viscosity index of the study group were better than those of the conventional group(P<0.05).Conclusion Shenxian Shengmai Oral Liquid combined with Isosorbide Mononitrate Capsule in the treatment of elderly patients with coronary heart disease and bradyarrhythmia has significant effect.The treatment can effectively reduce adverse reactions,relieves clinical symptoms,and is worthy of promotion.